| 1 | consecutive | 10,871 |
| 2 | nonconsecutive | 46 |
| 3 | non-consecutive | 37 |
| 4 | ceftazidime-treated | 12 |
| 5 | dmard-naive | 8 |
| 6 | iu/3 | 8 |
| 7 | fractions/3 | 7 |
| 8 | ab-positive | 6 |
| 9 | hmpv-positive | 6 |
| 10 | non-institutionalised | 6 |
| 11 | nonduplicate | 6 |
| 12 | community-recruited | 5 |
| 13 | days-12 | 5 |
| 14 | mg/28 | 5 |
| 15 | months.the | 5 |
| 16 | weeks-6 | 5 |
| 17 | afq056-treated | 4 |
| 18 | azt-experienced | 4 |
| 19 | childish | 4 |
| 20 | consecutives | 4 |
| 21 | days.the | 4 |
| 22 | ecallantide-treated | 4 |
| 23 | hla-a*0201-positive | 4 |
| 24 | low-sdc | 4 |
| 25 | relapsed/resistant | 4 |
| 26 | teduglutide-treated | 4 |
| 27 | 063 | 3 |
| 28 | 066 | 3 |
| 29 | 28-wk-old | 3 |
| 30 | 8056 | 3 |
| 31 | cad106-treated | 3 |
| 32 | cd40l-deficient | 3 |
| 33 | cefuroxime-treated | 3 |
| 34 | csii-treated | 3 |
| 35 | gentamicin-treated | 3 |
| 36 | glimepiride-treated | 3 |
| 37 | hla-a2-positive | 3 |
| 38 | hundred-five | 3 |
| 39 | hypoxia-positive | 3 |
| 40 | meperidine-treated | 3 |
| 41 | minimal-congestion | 3 |
| 42 | months-12 | 3 |
| 43 | mu/min/g | 3 |
| 44 | non-coplanar | 3 |
| 45 | nonduplicated | 3 |
| 46 | nonthreshold | 3 |
| 47 | patient-exposure | 3 |
| 48 | pegfilgrastim-treated | 3 |
| 49 | subcytotoxic | 3 |
| 50 | vitrification-warming | 3 |
| 51 | water/7 | 3 |
| 52 | μg-treated | 3 |
| 53 | /172 | 2 |
| 54 | /515 | 2 |
| 55 | 10,050 | 2 |
| 56 | 17,8 | 2 |
| 57 | 18,441 | 2 |
| 58 | 2,249 | 2 |
| 59 | 2,743 | 2 |
| 60 | 2-row | 2 |
| 61 | 3,968 | 2 |
| 62 | 3684 | 2 |
| 63 | 3703 | 2 |
| 64 | 4968 | 2 |
| 65 | 5,052 | 2 |
| 66 | age-gender-matched | 2 |
| 67 | and12 | 2 |
| 68 | anti-hmgcr-positive | 2 |
| 69 | asai-iii | 2 |
| 70 | aza/mp-treated | 2 |
| 71 | biopsy-naive | 2 |
| 72 | bmmsc-treated | 2 |
| 73 | cefpodoxime-treated | 2 |
| 74 | cervical-carcinoma | 2 |
| 75 | cigarettes/day/9 | 2 |
| 76 | corticosteroid-naive | 2 |
| 77 | days-3 | 2 |
| 78 | days-4 | 2 |
| 79 | days-6 | 2 |
| 80 | days/1,000 | 2 |
| 81 | days/8 | 2 |
| 82 | db-trial | 2 |
| 83 | dddr-randomized | 2 |
| 84 | diet-stable | 2 |
| 85 | ecuadorean | 2 |
| 86 | end-point-free | 2 |
| 87 | events/5295 | 2 |
| 88 | gcr-allergic | 2 |
| 89 | gy/4 | 2 |
| 90 | gy/7 | 2 |
| 91 | heat-action | 2 |
| 92 | hisex | 2 |
| 93 | hmcs2-deficient | 2 |
| 94 | indacaterol-treated | 2 |
| 95 | irs-iii | 2 |
| 96 | kg/4 | 2 |
| 97 | lakh | 2 |
| 98 | leukopenic | 2 |
| 99 | light-entrained | 2 |
| 100 | loratadine-treated | 2 |
| 101 | medically-treated | 2 |
| 102 | mg/day/4 | 2 |
| 103 | mg/kg/2 | 2 |
| 104 | moderate/heavily | 2 |
| 105 | neostigmine-treated | 2 |
| 106 | non-adopted | 2 |
| 107 | non-ecfi | 2 |
| 108 | non-fmr | 2 |
| 109 | non-ids | 2 |
| 110 | non-scalp-cooled | 2 |
| 111 | non-transferred | 2 |
| 112 | nonedentulous | 2 |
| 113 | nonexiting | 2 |
| 114 | nonpremedicated | 2 |
| 115 | normal-paced | 2 |
| 116 | normal-pregnant | 2 |
| 117 | nullipar | 2 |
| 118 | patient-hospital | 2 |
| 119 | patients/ | 2 |
| 120 | pcp-suspected | 2 |
| 121 | physician-referred | 2 |
| 122 | pirfenidone-treated | 2 |
| 123 | pk-evaluable | 2 |
| 124 | pretur | 2 |
| 125 | proteins/protein | 2 |
| 126 | pufa-treated | 2 |
| 127 | pupil/adult | 2 |
| 128 | resident-care | 2 |
| 129 | rhfsc-treated | 2 |
| 130 | ridt-negative | 2 |
| 131 | sham-gvc | 2 |
| 132 | shelter-owned | 2 |
| 133 | sra-positive | 2 |
| 134 | sugammadex-treated | 2 |
| 135 | t-dm1-exposed | 2 |
| 136 | terfenadine-treated | 2 |
| 137 | tofacitinib-treated | 2 |
| 138 | toxicity-suspected | 2 |
| 139 | trazodone-treated | 2 |
| 140 | undialyzed | 2 |
| 141 | years.no | 2 |
| 142 | 'audit | 1 |
| 143 | +/-251 | 1 |
| 144 | +/-34 | 1 |
| 145 | +/-364 | 1 |
| 146 | +/-40 | 1 |
| 147 | +/-47 | 1 |
| 148 | +/-55 | 1 |
| 149 | ,724 | 1 |
| 150 | -468 | 1 |
| 151 | -725 | 1 |
| 152 | /-21 | 1 |
| 153 | 10,008 | 1 |
| 154 | 10-65-year-old | 1 |
| 155 | 100,429 | 1 |
| 156 | 107,349 | 1 |
| 157 | 11,953 | 1 |
| 158 | 11-33-year-old | 1 |
| 159 | 13,635 | 1 |
| 160 | 1418+/-1668 | 1 |
| 161 | 15,524 | 1 |
| 162 | 16.3/50.0 | 1 |
| 163 | 17,398 | 1 |
| 164 | 18-member | 1 |
| 165 | 19-wk-old | 1 |
| 166 | 2-footed | 1 |
| 167 | 24,525 | 1 |
| 168 | 250-cgy | 1 |
| 169 | 26,496 | 1 |
| 170 | 3-7-year-old | 1 |
| 171 | 35,191 | 1 |
| 172 | 36,467 | 1 |
| 173 | 4,551 | 1 |
| 174 | 4-10-year-old | 1 |
| 175 | 45-75-year-old | 1 |
| 176 | 5,324 | 1 |
| 177 | 6148 | 1 |
| 178 | 65,676 | 1 |
| 179 | 6q-linked | 1 |
| 180 | 7-11-year-old | 1 |
| 181 | 7-12-year-old | 1 |
| 182 | 70±33 | 1 |
| 183 | 9860 | 1 |
| 184 | aceclofenac-treated | 1 |
| 185 | acl-insufficient | 1 |
| 186 | admission/24 | 1 |
| 187 | admissions/36 | 1 |
| 188 | adultcretan | 1 |
| 189 | agitation-exhibiting | 1 |
| 190 | agonist-naïve | 1 |
| 191 | alert-positive | 1 |
| 192 | alprazolam-dependent | 1 |
| 193 | ama-m2-negative/ana-positive | 1 |
| 194 | anaesthestised | 1 |
| 195 | and-forty-seven | 1 |
| 196 | and16 | 1 |
| 197 | anterior/7 | 1 |
| 198 | antiplatelet-treated | 1 |
| 199 | antipsychotic-short-exposure | 1 |
| 200 | applications/2 | 1 |
| 201 | arc/ks | 1 |
| 202 | aruba-eligible | 1 |
| 203 | aryloxy-1,3,4-thiadiazole | 1 |
| 204 | aspirin-naive | 1 |
| 205 | aspirinated | 1 |
| 206 | asunaprevir-treated | 1 |
| 207 | atacicept-treated | 1 |
| 208 | aur-treated | 1 |
| 209 | authors.the | 1 |
| 210 | az/amp-treated | 1 |
| 211 | bapineuzumab-treated | 1 |
| 212 | bcg-responding | 1 |
| 213 | bc~221 | 1 |
| 214 | bioct-arm | 1 |
| 215 | biopsy-naïve | 1 |
| 216 | bladder-catheter | 1 |
| 217 | blindsighted | 1 |
| 218 | bosentan-treated | 1 |
| 219 | brinzolamide-treated | 1 |
| 220 | c-steel | 1 |
| 221 | c.c.a | 1 |
| 222 | carbapenemase-negative | 1 |
| 223 | cardiosuigical | 1 |
| 224 | cases-4 | 1 |
| 225 | cefetamet-treated | 1 |
| 226 | centers:17 | 1 |
| 227 | cervico | 1 |
| 228 | circumferential-type | 1 |
| 229 | clinical/subclinical | 1 |
| 230 | clinically-evaluable | 1 |
| 231 | clinically-stable | 1 |
| 232 | clofibrate-resistant | 1 |
| 233 | clopidogrel-assigned | 1 |
| 234 | clz-treated | 1 |
| 235 | co-rated | 1 |
| 236 | coating/sampling/analysis | 1 |
| 237 | cocaine-misusing | 1 |
| 238 | colestipol-treated | 1 |
| 239 | collaterals-1,064 | 1 |
| 240 | colonoscopy-validated | 1 |
| 241 | community-representative | 1 |
| 242 | community-resident | 1 |
| 243 | comprised195 | 1 |
| 244 | consecution | 1 |
| 245 | consecutively-chosen | 1 |
| 246 | consultations/6 | 1 |
| 247 | continuous/62 | 1 |
| 248 | controlled-essential | 1 |
| 249 | copd-diagnosed | 1 |
| 250 | cr-predicted | 1 |
| 251 | cross-track | 1 |
| 252 | crt-indicated | 1 |
| 253 | crt-treated | 1 |
| 254 | ct-arm | 1 |
| 255 | cuscc/ka | 1 |
| 256 | cyclophosphamide-exposed | 1 |
| 257 | days+5 | 1 |
| 258 | days-120 | 1 |
| 259 | days-18 | 1 |
| 260 | days-24 | 1 |
| 261 | days-28.1 | 1 |
| 262 | days-35 | 1 |
| 263 | days-52 | 1 |
| 264 | days/166 | 1 |
| 265 | days/297 | 1 |
| 266 | dbcg82bc | 1 |
| 267 | deaths/105 | 1 |
| 268 | deaths/4871 | 1 |
| 269 | decitabine-treated | 1 |
| 270 | deoxyoligonucleotide | 1 |
| 271 | des-implanted | 1 |
| 272 | desulfurization-regeneration | 1 |
| 273 | diet-stabilized | 1 |
| 274 | diphenylhydantoin-treated | 1 |
| 275 | dis-depressed | 1 |
| 276 | dmard-treated | 1 |
| 277 | dpb-complicated | 1 |
| 278 | dth-positive | 1 |
| 279 | dtr-preserved | 1 |
| 280 | dyspnea-limited | 1 |
| 281 | ea/sa | 1 |
| 282 | early-responding | 1 |
| 283 | either-sex | 1 |
| 284 | em/43 | 1 |
| 285 | emesis-questionnaire | 1 |
| 286 | episodes/62 | 1 |
| 287 | episodes/63 | 1 |
| 288 | epoetin-eligible | 1 |
| 289 | equi-angular | 1 |
| 290 | eradication-failure | 1 |
| 291 | erg-negative | 1 |
| 292 | esotropic | 1 |
| 293 | etiology-positive | 1 |
| 294 | ett-group | 1 |
| 295 | euthyroidal | 1 |
| 296 | evaluatable | 1 |
| 297 | fall-born | 1 |
| 298 | first-stimulated | 1 |
| 299 | five-forty | 1 |
| 300 | fluastatin | 1 |
| 301 | fluid-therapy | 1 |
| 302 | flupentixol-treated | 1 |
| 303 | formaldehyde-allergic | 1 |
| 304 | fractions/14 | 1 |
| 305 | fractions/15 | 1 |
| 306 | frequentlyin | 1 |
| 307 | gal-treated | 1 |
| 308 | gastrititis | 1 |
| 309 | gen-treated | 1 |
| 310 | genetically-linked | 1 |
| 311 | geropsychiatry | 1 |
| 312 | glaucomatous/oht | 1 |
| 313 | glucocorticoid-naive | 1 |
| 314 | gonarthrosic | 1 |
| 315 | graft-derived | 1 |
| 316 | groups-150 | 1 |
| 317 | groups-26 | 1 |
| 318 | groups.ten | 1 |
| 319 | gsk679586-treated | 1 |
| 320 | gy/2-3 | 1 |
| 321 | gy/3-4 | 1 |
| 322 | gy/30fx/19 | 1 |
| 323 | gynecologic-pediatric | 1 |
| 324 | h/2 | 1 |
| 325 | h1n1-infected | 1 |
| 326 | h7n9-infected | 1 |
| 327 | haemarthroses | 1 |
| 328 | hemo-dynamically | 1 |
| 329 | heparin-group | 1 |
| 330 | hernia-repair | 1 |
| 331 | hexakaidecahedral | 1 |
| 332 | high-consumer | 1 |
| 333 | hiv/adis | 1 |
| 334 | hla-a*0201-negative | 1 |
| 335 | hours-28 | 1 |
| 336 | hours-30 | 1 |
| 337 | hpev3-positive | 1 |
| 338 | htbii-positive | 1 |
| 339 | hundred-thirty-four | 1 |
| 340 | hundred-twelve | 1 |
| 341 | hyperalimented | 1 |
| 342 | hypertensive-hypertrophic | 1 |
| 343 | hypo-anergic | 1 |
| 344 | icd/crt-d | 1 |
| 345 | id/autism | 1 |
| 346 | ifnb-1b-treated | 1 |
| 347 | ihc++ | 1 |
| 348 | ihc+++ | 1 |
| 349 | in-compliant | 1 |
| 350 | induction-eligible | 1 |
| 351 | infants≤4 | 1 |
| 352 | infection-bearing | 1 |
| 353 | inguinal-hernia | 1 |
| 354 | interval-detected | 1 |
| 355 | irs-i/ii | 1 |
| 356 | itt/complete | 1 |
| 357 | iu-group | 1 |
| 358 | jocob | 1 |
| 359 | knee-osteoarthritic | 1 |
| 360 | known-age | 1 |
| 361 | kras-evaluable | 1 |
| 362 | levodopa-naïve | 1 |
| 363 | levodopa/selegiline-treated | 1 |
| 364 | limited-activity | 1 |
| 365 | lm75/25-treated | 1 |
| 366 | lopinavir-ritonavir-treated | 1 |
| 367 | loup | 1 |
| 368 | luliconazole-treated | 1 |
| 369 | lung-transplanted | 1 |
| 370 | ly545694-treated | 1 |
| 371 | male/112 | 1 |
| 372 | male/167 | 1 |
| 373 | male/3 | 1 |
| 374 | male/36 | 1 |
| 375 | mat-positive | 1 |
| 376 | mayo-negative/ieo-positive | 1 |
| 377 | mg-2.59 | 1 |
| 378 | mg-in | 1 |
| 379 | mg/21 | 1 |
| 380 | mg/body/dayx28 | 1 |
| 381 | mg/day/14 | 1 |
| 382 | mg/day/7 | 1 |
| 383 | mg/kg/10 | 1 |
| 384 | mg/sb/kg/day/20 | 1 |
| 385 | miami-based | 1 |
| 386 | microbiologically-assessable | 1 |
| 387 | midodrine-treated | 1 |
| 388 | min/day-by-12 | 1 |
| 389 | miravirsen-treated | 1 |
| 390 | mite-treated | 1 |
| 391 | mitral-stenosis | 1 |
| 392 | ml/hr.all | 1 |
| 393 | ml/hr.the | 1 |
| 394 | ml/kg/week/6 | 1 |
| 395 | mmhg.the | 1 |
| 396 | moclobemide-treated | 1 |
| 397 | months-135 | 1 |
| 398 | months-145 | 1 |
| 399 | months-165 | 1 |
| 400 | months-175 | 1 |
| 401 | months.610 | 1 |
| 402 | months.8 | 1 |
| 403 | movement-disorder | 1 |
| 404 | mpo-anca-positive | 1 |
| 405 | mptp-parkinsonian | 1 |
| 406 | multiinfected | 1 |
| 407 | mustard-operated | 1 |
| 408 | mxf-treated | 1 |
| 409 | mycophenolate/dexamethasone-treated | 1 |
| 410 | new-to-dialysis | 1 |
| 411 | newly-detected | 1 |
| 412 | nicdm | 1 |
| 413 | nicotinamide-receiving | 1 |
| 414 | nights/3 | 1 |
| 415 | nis/100 | 1 |
| 416 | no-stroke | 1 |
| 417 | non-aapi | 1 |
| 418 | non-adjoining | 1 |
| 419 | non-cr-predicted | 1 |
| 420 | non-csa-treated | 1 |
| 421 | non-digitalized | 1 |
| 422 | non-down-syndrome | 1 |
| 423 | non-ics-treated | 1 |
| 424 | non-iondt | 1 |
| 425 | non-lts | 1 |
| 426 | non-mbl-producing | 1 |
| 427 | non-mpm | 1 |
| 428 | non-periprocedural | 1 |
| 429 | non-psoriasis | 1 |
| 430 | non-pusher | 1 |
| 431 | non-reflux | 1 |
| 432 | non-trd | 1 |
| 433 | non-txa | 1 |
| 434 | nonpmi | 1 |
| 435 | nonstatin-treated | 1 |
| 436 | normocitraturic | 1 |
| 437 | normophosphataemic | 1 |
| 438 | norwegian-speaking | 1 |
| 439 | nulipara | 1 |
| 440 | observations/245 | 1 |
| 441 | okt3-rescue | 1 |
| 442 | ols/25 | 1 |
| 443 | one-hen | 1 |
| 444 | opioid-agonist-maintained | 1 |
| 445 | optimally-treated | 1 |
| 446 | p16-methylated | 1 |
| 447 | pack-a-day | 1 |
| 448 | paper-paper | 1 |
| 449 | pathways-a | 1 |
| 450 | patients-hospitalization | 1 |
| 451 | patients/135 | 1 |
| 452 | patients/26 | 1 |
| 453 | patients:538 | 1 |
| 454 | pca/ifa-positive | 1 |
| 455 | per-protocol-treated | 1 |
| 456 | person-week | 1 |
| 457 | phase-adjusted | 1 |
| 458 | phase-lag | 1 |
| 459 | photoprovocable | 1 |
| 460 | platelet-transfused | 1 |
| 461 | post-esophagectomy | 1 |
| 462 | postia | 1 |
| 463 | pre/hypertensive | 1 |
| 464 | pregnany | 1 |
| 465 | prehydronephrosis | 1 |
| 466 | protozoosis | 1 |
| 467 | pss-negative | 1 |
| 468 | pushrim-activated | 1 |
| 469 | quetiapine-medicated | 1 |
| 470 | r-huepo-treated | 1 |
| 471 | racat | 1 |
| 472 | radioulcer | 1 |
| 473 | rads/2 | 1 |
| 474 | rads/5 | 1 |
| 475 | randomly-chosen | 1 |
| 476 | range,1-4 | 1 |
| 477 | re-assayed | 1 |
| 478 | recombinant-inbred | 1 |
| 479 | recon-enrolled | 1 |
| 480 | refluxive | 1 |
| 481 | relaxin-treated | 1 |
| 482 | retreatment-eligible | 1 |
| 483 | rhai | 1 |
| 484 | rheem | 1 |
| 485 | rif-resistant | 1 |
| 486 | robatumumab-treated | 1 |
| 487 | rtis/6 | 1 |
| 488 | saf-preserved | 1 |
| 489 | sargramostim-treated | 1 |
| 490 | seconds/30 | 1 |
| 491 | selegiline-treated | 1 |
| 492 | serologically-confirmed | 1 |
| 493 | sinus-lifted | 1 |
| 494 | sle-hospitalised | 1 |
| 495 | sp-infected | 1 |
| 496 | split-sex | 1 |
| 497 | srs-eligible | 1 |
| 498 | stabilized-schizophrenia | 1 |
| 499 | stable-copd | 1 |
| 500 | statin-tolerant | 1 |
| 501 | studies/180 | 1 |
| 502 | studies/2027 | 1 |
| 503 | studies/417 | 1 |
| 504 | subfasical | 1 |
| 505 | subjects/246 | 1 |
| 506 | summer-form | 1 |
| 507 | sunlight-powered | 1 |
| 508 | supine-positioned | 1 |
| 509 | surgery-group | 1 |
| 510 | surgical-urological | 1 |
| 511 | survivors/10,000 | 1 |
| 512 | sutezolid-treated | 1 |
| 513 | symptoms-free | 1 |
| 514 | systane-treated | 1 |
| 515 | systemically-healthy | 1 |
| 516 | t1-l1 | 1 |
| 517 | t1-t4n0m0 | 1 |
| 518 | tesaglitazar-treated | 1 |
| 519 | tests/60 | 1 |
| 520 | tetracycline-treated | 1 |
| 521 | tetrakaidecahedral | 1 |
| 522 | tgb-treated | 1 |
| 523 | thommen | 1 |
| 524 | thrmbocytopenic | 1 |
| 525 | thrombolytic-eligible | 1 |
| 526 | tilt-positive | 1 |
| 527 | times/12 | 1 |
| 528 | times/30 | 1 |
| 529 | tka-operated | 1 |
| 530 | tmr-treated | 1 |
| 531 | tne-naïve | 1 |
| 532 | to7 | 1 |
| 533 | tourette's/rage | 1 |
| 534 | tracheostomised | 1 |
| 535 | treatmentfree | 1 |
| 536 | tsab-negative | 1 |
| 537 | tsab-positive | 1 |
| 538 | two-second | 1 |
| 539 | ty-eight | 1 |
| 540 | unascertainable | 1 |
| 541 | undeterminable | 1 |
| 542 | up-to-2-week | 1 |
| 543 | vedolizumab-naive | 1 |
| 544 | ventilator-naïve | 1 |
| 545 | vgb-treated | 1 |
| 546 | vmp-treated | 1 |
| 547 | walpole | 1 |
| 548 | weeks+6 | 1 |
| 549 | weeks-12 | 1 |
| 550 | weeks-18 | 1 |
| 551 | weeks-22 | 1 |
| 552 | weeks-24 | 1 |
| 553 | weeks-3 | 1 |
| 554 | weeks-5 | 1 |
| 555 | weeks-72 | 1 |
| 556 | weeks±14 | 1 |
| 557 | wraadds-defined | 1 |
| 558 | xfs/xfg | 1 |
| 559 | years,33 | 1 |
| 560 | years-all | 1 |
| 561 | years.eighty-one | 1 |
| 562 | yspsl-treated | 1 |
| 563 | °c/500,000 | 1 |
| 564 | μg/48 | 1 |
| 565 | μg/cvl | 1 |
| 566 | μg/d×12 | 1 |
| 1 | 'audit | 1 |
| 2 | +/-251 | 1 |
| 3 | +/-34 | 1 |
| 4 | +/-364 | 1 |
| 5 | +/-40 | 1 |
| 6 | +/-47 | 1 |
| 7 | +/-55 | 1 |
| 8 | ,724 | 1 |
| 9 | -468 | 1 |
| 10 | -725 | 1 |
| 11 | /-21 | 1 |
| 12 | /172 | 2 |
| 13 | /515 | 2 |
| 14 | 063 | 3 |
| 15 | 066 | 3 |
| 16 | 10,008 | 1 |
| 17 | 10,050 | 2 |
| 18 | 10-65-year-old | 1 |
| 19 | 100,429 | 1 |
| 20 | 107,349 | 1 |
| 21 | 11,953 | 1 |
| 22 | 11-33-year-old | 1 |
| 23 | 13,635 | 1 |
| 24 | 1418+/-1668 | 1 |
| 25 | 15,524 | 1 |
| 26 | 16.3/50.0 | 1 |
| 27 | 17,398 | 1 |
| 28 | 17,8 | 2 |
| 29 | 18,441 | 2 |
| 30 | 18-member | 1 |
| 31 | 19-wk-old | 1 |
| 32 | 2,249 | 2 |
| 33 | 2,743 | 2 |
| 34 | 2-footed | 1 |
| 35 | 2-row | 2 |
| 36 | 24,525 | 1 |
| 37 | 250-cgy | 1 |
| 38 | 26,496 | 1 |
| 39 | 28-wk-old | 3 |
| 40 | 3,968 | 2 |
| 41 | 3-7-year-old | 1 |
| 42 | 35,191 | 1 |
| 43 | 36,467 | 1 |
| 44 | 3684 | 2 |
| 45 | 3703 | 2 |
| 46 | 4,551 | 1 |
| 47 | 4-10-year-old | 1 |
| 48 | 45-75-year-old | 1 |
| 49 | 4968 | 2 |
| 50 | 5,052 | 2 |
| 51 | 5,324 | 1 |
| 52 | 6148 | 1 |
| 53 | 65,676 | 1 |
| 54 | 6q-linked | 1 |
| 55 | 7-11-year-old | 1 |
| 56 | 7-12-year-old | 1 |
| 57 | 70±33 | 1 |
| 58 | 8056 | 3 |
| 59 | 9860 | 1 |
| 60 | ab-positive | 6 |
| 61 | aceclofenac-treated | 1 |
| 62 | acl-insufficient | 1 |
| 63 | admission/24 | 1 |
| 64 | admissions/36 | 1 |
| 65 | adultcretan | 1 |
| 66 | afq056-treated | 4 |
| 67 | age-gender-matched | 2 |
| 68 | agitation-exhibiting | 1 |
| 69 | agonist-naïve | 1 |
| 70 | alert-positive | 1 |
| 71 | alprazolam-dependent | 1 |
| 72 | ama-m2-negative/ana-positive | 1 |
| 73 | anaesthestised | 1 |
| 74 | and-forty-seven | 1 |
| 75 | and12 | 2 |
| 76 | and16 | 1 |
| 77 | anterior/7 | 1 |
| 78 | anti-hmgcr-positive | 2 |
| 79 | antiplatelet-treated | 1 |
| 80 | antipsychotic-short-exposure | 1 |
| 81 | applications/2 | 1 |
| 82 | arc/ks | 1 |
| 83 | aruba-eligible | 1 |
| 84 | aryloxy-1,3,4-thiadiazole | 1 |
| 85 | asai-iii | 2 |
| 86 | aspirin-naive | 1 |
| 87 | aspirinated | 1 |
| 88 | asunaprevir-treated | 1 |
| 89 | atacicept-treated | 1 |
| 90 | aur-treated | 1 |
| 91 | authors.the | 1 |
| 92 | az/amp-treated | 1 |
| 93 | aza/mp-treated | 2 |
| 94 | azt-experienced | 4 |
| 95 | bapineuzumab-treated | 1 |
| 96 | bcg-responding | 1 |
| 97 | bc~221 | 1 |
| 98 | bioct-arm | 1 |
| 99 | biopsy-naive | 2 |
| 100 | biopsy-naïve | 1 |
| 101 | bladder-catheter | 1 |
| 102 | blindsighted | 1 |
| 103 | bmmsc-treated | 2 |
| 104 | bosentan-treated | 1 |
| 105 | brinzolamide-treated | 1 |
| 106 | c-steel | 1 |
| 107 | c.c.a | 1 |
| 108 | cad106-treated | 3 |
| 109 | carbapenemase-negative | 1 |
| 110 | cardiosuigical | 1 |
| 111 | cases-4 | 1 |
| 112 | cd40l-deficient | 3 |
| 113 | cefetamet-treated | 1 |
| 114 | cefpodoxime-treated | 2 |
| 115 | ceftazidime-treated | 12 |
| 116 | cefuroxime-treated | 3 |
| 117 | centers:17 | 1 |
| 118 | cervical-carcinoma | 2 |
| 119 | cervico | 1 |
| 120 | childish | 4 |
| 121 | cigarettes/day/9 | 2 |
| 122 | circumferential-type | 1 |
| 123 | clinical/subclinical | 1 |
| 124 | clinically-evaluable | 1 |
| 125 | clinically-stable | 1 |
| 126 | clofibrate-resistant | 1 |
| 127 | clopidogrel-assigned | 1 |
| 128 | clz-treated | 1 |
| 129 | co-rated | 1 |
| 130 | coating/sampling/analysis | 1 |
| 131 | cocaine-misusing | 1 |
| 132 | colestipol-treated | 1 |
| 133 | collaterals-1,064 | 1 |
| 134 | colonoscopy-validated | 1 |
| 135 | community-recruited | 5 |
| 136 | community-representative | 1 |
| 137 | community-resident | 1 |
| 138 | comprised195 | 1 |
| 139 | consecution | 1 |
| 140 | consecutive | 10,871 |
| 141 | consecutively-chosen | 1 |
| 142 | consecutives | 4 |
| 143 | consultations/6 | 1 |
| 144 | continuous/62 | 1 |
| 145 | controlled-essential | 1 |
| 146 | copd-diagnosed | 1 |
| 147 | corticosteroid-naive | 2 |
| 148 | cr-predicted | 1 |
| 149 | cross-track | 1 |
| 150 | crt-indicated | 1 |
| 151 | crt-treated | 1 |
| 152 | csii-treated | 3 |
| 153 | ct-arm | 1 |
| 154 | cuscc/ka | 1 |
| 155 | cyclophosphamide-exposed | 1 |
| 156 | days+5 | 1 |
| 157 | days-12 | 5 |
| 158 | days-120 | 1 |
| 159 | days-18 | 1 |
| 160 | days-24 | 1 |
| 161 | days-28.1 | 1 |
| 162 | days-3 | 2 |
| 163 | days-35 | 1 |
| 164 | days-4 | 2 |
| 165 | days-52 | 1 |
| 166 | days-6 | 2 |
| 167 | days.the | 4 |
| 168 | days/1,000 | 2 |
| 169 | days/166 | 1 |
| 170 | days/297 | 1 |
| 171 | days/8 | 2 |
| 172 | db-trial | 2 |
| 173 | dbcg82bc | 1 |
| 174 | dddr-randomized | 2 |
| 175 | deaths/105 | 1 |
| 176 | deaths/4871 | 1 |
| 177 | decitabine-treated | 1 |
| 178 | deoxyoligonucleotide | 1 |
| 179 | des-implanted | 1 |
| 180 | desulfurization-regeneration | 1 |
| 181 | diet-stabilized | 1 |
| 182 | diet-stable | 2 |
| 183 | diphenylhydantoin-treated | 1 |
| 184 | dis-depressed | 1 |
| 185 | dmard-naive | 8 |
| 186 | dmard-treated | 1 |
| 187 | dpb-complicated | 1 |
| 188 | dth-positive | 1 |
| 189 | dtr-preserved | 1 |
| 190 | dyspnea-limited | 1 |
| 191 | ea/sa | 1 |
| 192 | early-responding | 1 |
| 193 | ecallantide-treated | 4 |
| 194 | ecuadorean | 2 |
| 195 | either-sex | 1 |
| 196 | em/43 | 1 |
| 197 | emesis-questionnaire | 1 |
| 198 | end-point-free | 2 |
| 199 | episodes/62 | 1 |
| 200 | episodes/63 | 1 |
| 201 | epoetin-eligible | 1 |
| 202 | equi-angular | 1 |
| 203 | eradication-failure | 1 |
| 204 | erg-negative | 1 |
| 205 | esotropic | 1 |
| 206 | etiology-positive | 1 |
| 207 | ett-group | 1 |
| 208 | euthyroidal | 1 |
| 209 | evaluatable | 1 |
| 210 | events/5295 | 2 |
| 211 | fall-born | 1 |
| 212 | first-stimulated | 1 |
| 213 | five-forty | 1 |
| 214 | fluastatin | 1 |
| 215 | fluid-therapy | 1 |
| 216 | flupentixol-treated | 1 |
| 217 | formaldehyde-allergic | 1 |
| 218 | fractions/14 | 1 |
| 219 | fractions/15 | 1 |
| 220 | fractions/3 | 7 |
| 221 | frequentlyin | 1 |
| 222 | gal-treated | 1 |
| 223 | gastrititis | 1 |
| 224 | gcr-allergic | 2 |
| 225 | gen-treated | 1 |
| 226 | genetically-linked | 1 |
| 227 | gentamicin-treated | 3 |
| 228 | geropsychiatry | 1 |
| 229 | glaucomatous/oht | 1 |
| 230 | glimepiride-treated | 3 |
| 231 | glucocorticoid-naive | 1 |
| 232 | gonarthrosic | 1 |
| 233 | graft-derived | 1 |
| 234 | groups-150 | 1 |
| 235 | groups-26 | 1 |
| 236 | groups.ten | 1 |
| 237 | gsk679586-treated | 1 |
| 238 | gy/2-3 | 1 |
| 239 | gy/3-4 | 1 |
| 240 | gy/30fx/19 | 1 |
| 241 | gy/4 | 2 |
| 242 | gy/7 | 2 |
| 243 | gynecologic-pediatric | 1 |
| 244 | h/2 | 1 |
| 245 | h1n1-infected | 1 |
| 246 | h7n9-infected | 1 |
| 247 | haemarthroses | 1 |
| 248 | heat-action | 2 |
| 249 | hemo-dynamically | 1 |
| 250 | heparin-group | 1 |
| 251 | hernia-repair | 1 |
| 252 | hexakaidecahedral | 1 |
| 253 | high-consumer | 1 |
| 254 | hisex | 2 |
| 255 | hiv/adis | 1 |
| 256 | hla-a*0201-negative | 1 |
| 257 | hla-a*0201-positive | 4 |
| 258 | hla-a2-positive | 3 |
| 259 | hmcs2-deficient | 2 |
| 260 | hmpv-positive | 6 |
| 261 | hours-28 | 1 |
| 262 | hours-30 | 1 |
| 263 | hpev3-positive | 1 |
| 264 | htbii-positive | 1 |
| 265 | hundred-five | 3 |
| 266 | hundred-thirty-four | 1 |
| 267 | hundred-twelve | 1 |
| 268 | hyperalimented | 1 |
| 269 | hypertensive-hypertrophic | 1 |
| 270 | hypo-anergic | 1 |
| 271 | hypoxia-positive | 3 |
| 272 | icd/crt-d | 1 |
| 273 | id/autism | 1 |
| 274 | ifnb-1b-treated | 1 |
| 275 | ihc++ | 1 |
| 276 | ihc+++ | 1 |
| 277 | in-compliant | 1 |
| 278 | indacaterol-treated | 2 |
| 279 | induction-eligible | 1 |
| 280 | infants≤4 | 1 |
| 281 | infection-bearing | 1 |
| 282 | inguinal-hernia | 1 |
| 283 | interval-detected | 1 |
| 284 | irs-i/ii | 1 |
| 285 | irs-iii | 2 |
| 286 | itt/complete | 1 |
| 287 | iu-group | 1 |
| 288 | iu/3 | 8 |
| 289 | jocob | 1 |
| 290 | kg/4 | 2 |
| 291 | knee-osteoarthritic | 1 |
| 292 | known-age | 1 |
| 293 | kras-evaluable | 1 |
| 294 | lakh | 2 |
| 295 | leukopenic | 2 |
| 296 | levodopa-naïve | 1 |
| 297 | levodopa/selegiline-treated | 1 |
| 298 | light-entrained | 2 |
| 299 | limited-activity | 1 |
| 300 | lm75/25-treated | 1 |
| 301 | lopinavir-ritonavir-treated | 1 |
| 302 | loratadine-treated | 2 |
| 303 | loup | 1 |
| 304 | low-sdc | 4 |
| 305 | luliconazole-treated | 1 |
| 306 | lung-transplanted | 1 |
| 307 | ly545694-treated | 1 |
| 308 | male/112 | 1 |
| 309 | male/167 | 1 |
| 310 | male/3 | 1 |
| 311 | male/36 | 1 |
| 312 | mat-positive | 1 |
| 313 | mayo-negative/ieo-positive | 1 |
| 314 | medically-treated | 2 |
| 315 | meperidine-treated | 3 |
| 316 | mg-2.59 | 1 |
| 317 | mg-in | 1 |
| 318 | mg/21 | 1 |
| 319 | mg/28 | 5 |
| 320 | mg/body/dayx28 | 1 |
| 321 | mg/day/14 | 1 |
| 322 | mg/day/4 | 2 |
| 323 | mg/day/7 | 1 |
| 324 | mg/kg/10 | 1 |
| 325 | mg/kg/2 | 2 |
| 326 | mg/sb/kg/day/20 | 1 |
| 327 | miami-based | 1 |
| 328 | microbiologically-assessable | 1 |
| 329 | midodrine-treated | 1 |
| 330 | min/day-by-12 | 1 |
| 331 | minimal-congestion | 3 |
| 332 | miravirsen-treated | 1 |
| 333 | mite-treated | 1 |
| 334 | mitral-stenosis | 1 |
| 335 | ml/hr.all | 1 |
| 336 | ml/hr.the | 1 |
| 337 | ml/kg/week/6 | 1 |
| 338 | mmhg.the | 1 |
| 339 | moclobemide-treated | 1 |
| 340 | moderate/heavily | 2 |
| 341 | months-12 | 3 |
| 342 | months-135 | 1 |
| 343 | months-145 | 1 |
| 344 | months-165 | 1 |
| 345 | months-175 | 1 |
| 346 | months.610 | 1 |
| 347 | months.8 | 1 |
| 348 | months.the | 5 |
| 349 | movement-disorder | 1 |
| 350 | mpo-anca-positive | 1 |
| 351 | mptp-parkinsonian | 1 |
| 352 | mu/min/g | 3 |
| 353 | multiinfected | 1 |
| 354 | mustard-operated | 1 |
| 355 | mxf-treated | 1 |
| 356 | mycophenolate/dexamethasone-treated | 1 |
| 357 | neostigmine-treated | 2 |
| 358 | new-to-dialysis | 1 |
| 359 | newly-detected | 1 |
| 360 | nicdm | 1 |
| 361 | nicotinamide-receiving | 1 |
| 362 | nights/3 | 1 |
| 363 | nis/100 | 1 |
| 364 | no-stroke | 1 |
| 365 | non-aapi | 1 |
| 366 | non-adjoining | 1 |
| 367 | non-adopted | 2 |
| 368 | non-consecutive | 37 |
| 369 | non-coplanar | 3 |
| 370 | non-cr-predicted | 1 |
| 371 | non-csa-treated | 1 |
| 372 | non-digitalized | 1 |
| 373 | non-down-syndrome | 1 |
| 374 | non-ecfi | 2 |
| 375 | non-fmr | 2 |
| 376 | non-ics-treated | 1 |
| 377 | non-ids | 2 |
| 378 | non-institutionalised | 6 |
| 379 | non-iondt | 1 |
| 380 | non-lts | 1 |
| 381 | non-mbl-producing | 1 |
| 382 | non-mpm | 1 |
| 383 | non-periprocedural | 1 |
| 384 | non-psoriasis | 1 |
| 385 | non-pusher | 1 |
| 386 | non-reflux | 1 |
| 387 | non-scalp-cooled | 2 |
| 388 | non-transferred | 2 |
| 389 | non-trd | 1 |
| 390 | non-txa | 1 |
| 391 | nonconsecutive | 46 |
| 392 | nonduplicate | 6 |
| 393 | nonduplicated | 3 |
| 394 | nonedentulous | 2 |
| 395 | nonexiting | 2 |
| 396 | nonpmi | 1 |
| 397 | nonpremedicated | 2 |
| 398 | nonstatin-treated | 1 |
| 399 | nonthreshold | 3 |
| 400 | normal-paced | 2 |
| 401 | normal-pregnant | 2 |
| 402 | normocitraturic | 1 |
| 403 | normophosphataemic | 1 |
| 404 | norwegian-speaking | 1 |
| 405 | nulipara | 1 |
| 406 | nullipar | 2 |
| 407 | observations/245 | 1 |
| 408 | okt3-rescue | 1 |
| 409 | ols/25 | 1 |
| 410 | one-hen | 1 |
| 411 | opioid-agonist-maintained | 1 |
| 412 | optimally-treated | 1 |
| 413 | p16-methylated | 1 |
| 414 | pack-a-day | 1 |
| 415 | paper-paper | 1 |
| 416 | pathways-a | 1 |
| 417 | patient-exposure | 3 |
| 418 | patient-hospital | 2 |
| 419 | patients-hospitalization | 1 |
| 420 | patients/ | 2 |
| 421 | patients/135 | 1 |
| 422 | patients/26 | 1 |
| 423 | patients:538 | 1 |
| 424 | pca/ifa-positive | 1 |
| 425 | pcp-suspected | 2 |
| 426 | pegfilgrastim-treated | 3 |
| 427 | per-protocol-treated | 1 |
| 428 | person-week | 1 |
| 429 | phase-adjusted | 1 |
| 430 | phase-lag | 1 |
| 431 | photoprovocable | 1 |
| 432 | physician-referred | 2 |
| 433 | pirfenidone-treated | 2 |
| 434 | pk-evaluable | 2 |
| 435 | platelet-transfused | 1 |
| 436 | post-esophagectomy | 1 |
| 437 | postia | 1 |
| 438 | pre/hypertensive | 1 |
| 439 | pregnany | 1 |
| 440 | prehydronephrosis | 1 |
| 441 | pretur | 2 |
| 442 | proteins/protein | 2 |
| 443 | protozoosis | 1 |
| 444 | pss-negative | 1 |
| 445 | pufa-treated | 2 |
| 446 | pupil/adult | 2 |
| 447 | pushrim-activated | 1 |
| 448 | quetiapine-medicated | 1 |
| 449 | r-huepo-treated | 1 |
| 450 | racat | 1 |
| 451 | radioulcer | 1 |
| 452 | rads/2 | 1 |
| 453 | rads/5 | 1 |
| 454 | randomly-chosen | 1 |
| 455 | range,1-4 | 1 |
| 456 | re-assayed | 1 |
| 457 | recombinant-inbred | 1 |
| 458 | recon-enrolled | 1 |
| 459 | refluxive | 1 |
| 460 | relapsed/resistant | 4 |
| 461 | relaxin-treated | 1 |
| 462 | resident-care | 2 |
| 463 | retreatment-eligible | 1 |
| 464 | rhai | 1 |
| 465 | rheem | 1 |
| 466 | rhfsc-treated | 2 |
| 467 | ridt-negative | 2 |
| 468 | rif-resistant | 1 |
| 469 | robatumumab-treated | 1 |
| 470 | rtis/6 | 1 |
| 471 | saf-preserved | 1 |
| 472 | sargramostim-treated | 1 |
| 473 | seconds/30 | 1 |
| 474 | selegiline-treated | 1 |
| 475 | serologically-confirmed | 1 |
| 476 | sham-gvc | 2 |
| 477 | shelter-owned | 2 |
| 478 | sinus-lifted | 1 |
| 479 | sle-hospitalised | 1 |
| 480 | sp-infected | 1 |
| 481 | split-sex | 1 |
| 482 | sra-positive | 2 |
| 483 | srs-eligible | 1 |
| 484 | stabilized-schizophrenia | 1 |
| 485 | stable-copd | 1 |
| 486 | statin-tolerant | 1 |
| 487 | studies/180 | 1 |
| 488 | studies/2027 | 1 |
| 489 | studies/417 | 1 |
| 490 | subcytotoxic | 3 |
| 491 | subfasical | 1 |
| 492 | subjects/246 | 1 |
| 493 | sugammadex-treated | 2 |
| 494 | summer-form | 1 |
| 495 | sunlight-powered | 1 |
| 496 | supine-positioned | 1 |
| 497 | surgery-group | 1 |
| 498 | surgical-urological | 1 |
| 499 | survivors/10,000 | 1 |
| 500 | sutezolid-treated | 1 |
| 501 | symptoms-free | 1 |
| 502 | systane-treated | 1 |
| 503 | systemically-healthy | 1 |
| 504 | t-dm1-exposed | 2 |
| 505 | t1-l1 | 1 |
| 506 | t1-t4n0m0 | 1 |
| 507 | teduglutide-treated | 4 |
| 508 | terfenadine-treated | 2 |
| 509 | tesaglitazar-treated | 1 |
| 510 | tests/60 | 1 |
| 511 | tetracycline-treated | 1 |
| 512 | tetrakaidecahedral | 1 |
| 513 | tgb-treated | 1 |
| 514 | thommen | 1 |
| 515 | thrmbocytopenic | 1 |
| 516 | thrombolytic-eligible | 1 |
| 517 | tilt-positive | 1 |
| 518 | times/12 | 1 |
| 519 | times/30 | 1 |
| 520 | tka-operated | 1 |
| 521 | tmr-treated | 1 |
| 522 | tne-naïve | 1 |
| 523 | to7 | 1 |
| 524 | tofacitinib-treated | 2 |
| 525 | tourette's/rage | 1 |
| 526 | toxicity-suspected | 2 |
| 527 | tracheostomised | 1 |
| 528 | trazodone-treated | 2 |
| 529 | treatmentfree | 1 |
| 530 | tsab-negative | 1 |
| 531 | tsab-positive | 1 |
| 532 | two-second | 1 |
| 533 | ty-eight | 1 |
| 534 | unascertainable | 1 |
| 535 | undeterminable | 1 |
| 536 | undialyzed | 2 |
| 537 | up-to-2-week | 1 |
| 538 | vedolizumab-naive | 1 |
| 539 | ventilator-naïve | 1 |
| 540 | vgb-treated | 1 |
| 541 | vitrification-warming | 3 |
| 542 | vmp-treated | 1 |
| 543 | walpole | 1 |
| 544 | water/7 | 3 |
| 545 | weeks+6 | 1 |
| 546 | weeks-12 | 1 |
| 547 | weeks-18 | 1 |
| 548 | weeks-22 | 1 |
| 549 | weeks-24 | 1 |
| 550 | weeks-3 | 1 |
| 551 | weeks-5 | 1 |
| 552 | weeks-6 | 5 |
| 553 | weeks-72 | 1 |
| 554 | weeks±14 | 1 |
| 555 | wraadds-defined | 1 |
| 556 | xfs/xfg | 1 |
| 557 | years,33 | 1 |
| 558 | years-all | 1 |
| 559 | years.eighty-one | 1 |
| 560 | years.no | 2 |
| 561 | yspsl-treated | 1 |
| 562 | °c/500,000 | 1 |
| 563 | μg-treated | 3 |
| 564 | μg/48 | 1 |
| 565 | μg/cvl | 1 |
| 566 | μg/d×12 | 1 |
| 1 | ihc+++ | 1 |
| 2 | ihc++ | 1 |
| 3 | patients/ | 2 |
| 4 | 16.3/50.0 | 1 |
| 5 | °c/500,000 | 1 |
| 6 | survivors/10,000 | 1 |
| 7 | days/1,000 | 2 |
| 8 | nis/100 | 1 |
| 9 | mg/kg/10 | 1 |
| 10 | months.610 | 1 |
| 11 | mg/sb/kg/day/20 | 1 |
| 12 | days-120 | 1 |
| 13 | hours-30 | 1 |
| 14 | seconds/30 | 1 |
| 15 | times/30 | 1 |
| 16 | +/-40 | 1 |
| 17 | 10,050 | 2 |
| 18 | groups-150 | 1 |
| 19 | tests/60 | 1 |
| 20 | 9860 | 1 |
| 21 | studies/180 | 1 |
| 22 | t1-t4n0m0 | 1 |
| 23 | days-28.1 | 1 |
| 24 | /-21 | 1 |
| 25 | mg/21 | 1 |
| 26 | bc~221 | 1 |
| 27 | 18,441 | 2 |
| 28 | +/-251 | 1 |
| 29 | 4,551 | 1 |
| 30 | deaths/4871 | 1 |
| 31 | 35,191 | 1 |
| 32 | t1-l1 | 1 |
| 33 | mg/kg/2 | 2 |
| 34 | h/2 | 1 |
| 35 | rads/2 | 1 |
| 36 | applications/2 | 1 |
| 37 | months-12 | 3 |
| 38 | weeks-12 | 1 |
| 39 | days-12 | 5 |
| 40 | min/day-by-12 | 1 |
| 41 | times/12 | 1 |
| 42 | male/112 | 1 |
| 43 | and12 | 2 |
| 44 | μg/d×12 | 1 |
| 45 | weeks-22 | 1 |
| 46 | days-52 | 1 |
| 47 | 5,052 | 2 |
| 48 | episodes/62 | 1 |
| 49 | continuous/62 | 1 |
| 50 | weeks-72 | 1 |
| 51 | /172 | 2 |
| 52 | gy/2-3 | 1 |
| 53 | weeks-3 | 1 |
| 54 | days-3 | 2 |
| 55 | male/3 | 1 |
| 56 | fractions/3 | 7 |
| 57 | nights/3 | 1 |
| 58 | iu/3 | 8 |
| 59 | 3703 | 2 |
| 60 | years,33 | 1 |
| 61 | 70±33 | 1 |
| 62 | em/43 | 1 |
| 63 | 2,743 | 2 |
| 64 | 11,953 | 1 |
| 65 | episodes/63 | 1 |
| 66 | 063 | 3 |
| 67 | range,1-4 | 1 |
| 68 | gy/3-4 | 1 |
| 69 | cases-4 | 1 |
| 70 | days-4 | 2 |
| 71 | kg/4 | 2 |
| 72 | mg/day/4 | 2 |
| 73 | gy/4 | 2 |
| 74 | fractions/14 | 1 |
| 75 | mg/day/14 | 1 |
| 76 | weeks±14 | 1 |
| 77 | weeks-24 | 1 |
| 78 | days-24 | 1 |
| 79 | admission/24 | 1 |
| 80 | 5,324 | 1 |
| 81 | 15,524 | 1 |
| 82 | ,724 | 1 |
| 83 | +/-34 | 1 |
| 84 | collaterals-1,064 | 1 |
| 85 | +/-364 | 1 |
| 86 | 3684 | 2 |
| 87 | infants≤4 | 1 |
| 88 | days+5 | 1 |
| 89 | weeks-5 | 1 |
| 90 | rads/5 | 1 |
| 91 | deaths/105 | 1 |
| 92 | fractions/15 | 1 |
| 93 | /515 | 2 |
| 94 | ols/25 | 1 |
| 95 | 24,525 | 1 |
| 96 | -725 | 1 |
| 97 | days-35 | 1 |
| 98 | months-135 | 1 |
| 99 | patients/135 | 1 |
| 100 | 13,635 | 1 |
| 101 | months-145 | 1 |
| 102 | observations/245 | 1 |
| 103 | +/-55 | 1 |
| 104 | months-165 | 1 |
| 105 | months-175 | 1 |
| 106 | comprised195 | 1 |
| 107 | events/5295 | 2 |
| 108 | weeks+6 | 1 |
| 109 | weeks-6 | 5 |
| 110 | days-6 | 2 |
| 111 | ml/kg/week/6 | 1 |
| 112 | rtis/6 | 1 |
| 113 | consultations/6 | 1 |
| 114 | and16 | 1 |
| 115 | groups-26 | 1 |
| 116 | patients/26 | 1 |
| 117 | male/36 | 1 |
| 118 | admissions/36 | 1 |
| 119 | subjects/246 | 1 |
| 120 | 8056 | 3 |
| 121 | 066 | 3 |
| 122 | days/166 | 1 |
| 123 | 65,676 | 1 |
| 124 | 26,496 | 1 |
| 125 | water/7 | 3 |
| 126 | anterior/7 | 1 |
| 127 | mg/day/7 | 1 |
| 128 | gy/7 | 2 |
| 129 | studies/417 | 1 |
| 130 | centers:17 | 1 |
| 131 | studies/2027 | 1 |
| 132 | +/-47 | 1 |
| 133 | male/167 | 1 |
| 134 | 36,467 | 1 |
| 135 | days/297 | 1 |
| 136 | to7 | 1 |
| 137 | 17,8 | 2 |
| 138 | months.8 | 1 |
| 139 | days/8 | 2 |
| 140 | 10,008 | 1 |
| 141 | weeks-18 | 1 |
| 142 | days-18 | 1 |
| 143 | hours-28 | 1 |
| 144 | mg/28 | 5 |
| 145 | mg/body/dayx28 | 1 |
| 146 | patients:538 | 1 |
| 147 | μg/48 | 1 |
| 148 | 6148 | 1 |
| 149 | -468 | 1 |
| 150 | 1418+/-1668 | 1 |
| 151 | 3,968 | 2 |
| 152 | 4968 | 2 |
| 153 | 17,398 | 1 |
| 154 | cigarettes/day/9 | 2 |
| 155 | gy/30fx/19 | 1 |
| 156 | 100,429 | 1 |
| 157 | 2,249 | 2 |
| 158 | 107,349 | 1 |
| 159 | mg-2.59 | 1 |
| 160 | pathways-a | 1 |
| 161 | c.c.a | 1 |
| 162 | stabilized-schizophrenia | 1 |
| 163 | inguinal-hernia | 1 |
| 164 | postia | 1 |
| 165 | cuscc/ka | 1 |
| 166 | cervical-carcinoma | 2 |
| 167 | nulipara | 1 |
| 168 | ea/sa | 1 |
| 169 | non-txa | 1 |
| 170 | jocob | 1 |
| 171 | dbcg82bc | 1 |
| 172 | low-sdc | 4 |
| 173 | formaldehyde-allergic | 1 |
| 174 | gcr-allergic | 2 |
| 175 | hypo-anergic | 1 |
| 176 | hypertensive-hypertrophic | 1 |
| 177 | normophosphataemic | 1 |
| 178 | leukopenic | 2 |
| 179 | thrmbocytopenic | 1 |
| 180 | esotropic | 1 |
| 181 | gynecologic-pediatric | 1 |
| 182 | normocitraturic | 1 |
| 183 | gonarthrosic | 1 |
| 184 | knee-osteoarthritic | 1 |
| 185 | subcytotoxic | 3 |
| 186 | sham-gvc | 2 |
| 187 | icd/crt-d | 1 |
| 188 | normal-paced | 2 |
| 189 | azt-experienced | 4 |
| 190 | age-gender-matched | 2 |
| 191 | 6q-linked | 1 |
| 192 | genetically-linked | 1 |
| 193 | recon-enrolled | 1 |
| 194 | non-scalp-cooled | 2 |
| 195 | serologically-confirmed | 1 |
| 196 | clopidogrel-assigned | 1 |
| 197 | light-entrained | 2 |
| 198 | opioid-agonist-maintained | 1 |
| 199 | wraadds-defined | 1 |
| 200 | supine-positioned | 1 |
| 201 | shelter-owned | 2 |
| 202 | recombinant-inbred | 1 |
| 203 | sunlight-powered | 1 |
| 204 | physician-referred | 2 |
| 205 | non-transferred | 2 |
| 206 | miami-based | 1 |
| 207 | non-institutionalised | 6 |
| 208 | sle-hospitalised | 1 |
| 209 | tracheostomised | 1 |
| 210 | anaesthestised | 1 |
| 211 | copd-diagnosed | 1 |
| 212 | t-dm1-exposed | 2 |
| 213 | cyclophosphamide-exposed | 1 |
| 214 | dis-depressed | 1 |
| 215 | platelet-transfused | 1 |
| 216 | quetiapine-medicated | 1 |
| 217 | nonpremedicated | 2 |
| 218 | crt-indicated | 1 |
| 219 | dpb-complicated | 1 |
| 220 | nonduplicated | 3 |
| 221 | colonoscopy-validated | 1 |
| 222 | ly545694-treated | 1 |
| 223 | lm75/25-treated | 1 |
| 224 | cad106-treated | 3 |
| 225 | afq056-treated | 4 |
| 226 | gsk679586-treated | 1 |
| 227 | pufa-treated | 2 |
| 228 | non-csa-treated | 1 |
| 229 | ifnb-1b-treated | 1 |
| 230 | robatumumab-treated | 1 |
| 231 | bapineuzumab-treated | 1 |
| 232 | tgb-treated | 1 |
| 233 | vgb-treated | 1 |
| 234 | tofacitinib-treated | 2 |
| 235 | aceclofenac-treated | 1 |
| 236 | rhfsc-treated | 2 |
| 237 | bmmsc-treated | 2 |
| 238 | sutezolid-treated | 1 |
| 239 | dmard-treated | 1 |
| 240 | brinzolamide-treated | 1 |
| 241 | moclobemide-treated | 1 |
| 242 | glimepiride-treated | 3 |
| 243 | ecallantide-treated | 4 |
| 244 | teduglutide-treated | 4 |
| 245 | luliconazole-treated | 1 |
| 246 | ceftazidime-treated | 12 |
| 247 | cefpodoxime-treated | 2 |
| 248 | cefuroxime-treated | 3 |
| 249 | systane-treated | 1 |
| 250 | decitabine-treated | 1 |
| 251 | terfenadine-treated | 2 |
| 252 | loratadine-treated | 2 |
| 253 | meperidine-treated | 3 |
| 254 | tetracycline-treated | 1 |
| 255 | selegiline-treated | 1 |
| 256 | levodopa/selegiline-treated | 1 |
| 257 | neostigmine-treated | 2 |
| 258 | midodrine-treated | 1 |
| 259 | pirfenidone-treated | 2 |
| 260 | trazodone-treated | 2 |
| 261 | mycophenolate/dexamethasone-treated | 1 |
| 262 | mite-treated | 1 |
| 263 | mxf-treated | 1 |
| 264 | μg-treated | 3 |
| 265 | csii-treated | 3 |
| 266 | gal-treated | 1 |
| 267 | per-protocol-treated | 1 |
| 268 | colestipol-treated | 1 |
| 269 | indacaterol-treated | 2 |
| 270 | flupentixol-treated | 1 |
| 271 | yspsl-treated | 1 |
| 272 | pegfilgrastim-treated | 3 |
| 273 | sargramostim-treated | 1 |
| 274 | bosentan-treated | 1 |
| 275 | gen-treated | 1 |
| 276 | miravirsen-treated | 1 |
| 277 | gentamicin-treated | 3 |
| 278 | diphenylhydantoin-treated | 1 |
| 279 | nonstatin-treated | 1 |
| 280 | relaxin-treated | 1 |
| 281 | r-huepo-treated | 1 |
| 282 | aza/mp-treated | 2 |
| 283 | az/amp-treated | 1 |
| 284 | vmp-treated | 1 |
| 285 | tesaglitazar-treated | 1 |
| 286 | lopinavir-ritonavir-treated | 1 |
| 287 | asunaprevir-treated | 1 |
| 288 | tmr-treated | 1 |
| 289 | aur-treated | 1 |
| 290 | non-ics-treated | 1 |
| 291 | antiplatelet-treated | 1 |
| 292 | cefetamet-treated | 1 |
| 293 | atacicept-treated | 1 |
| 294 | crt-treated | 1 |
| 295 | sugammadex-treated | 2 |
| 296 | medically-treated | 2 |
| 297 | optimally-treated | 1 |
| 298 | clz-treated | 1 |
| 299 | first-stimulated | 1 |
| 300 | p16-methylated | 1 |
| 301 | aspirinated | 1 |
| 302 | co-rated | 1 |
| 303 | tka-operated | 1 |
| 304 | mustard-operated | 1 |
| 305 | pushrim-activated | 1 |
| 306 | h1n1-infected | 1 |
| 307 | h7n9-infected | 1 |
| 308 | sp-infected | 1 |
| 309 | multiinfected | 1 |
| 310 | pcp-suspected | 2 |
| 311 | toxicity-suspected | 2 |
| 312 | interval-detected | 1 |
| 313 | newly-detected | 1 |
| 314 | cr-predicted | 1 |
| 315 | non-cr-predicted | 1 |
| 316 | sinus-lifted | 1 |
| 317 | blindsighted | 1 |
| 318 | dyspnea-limited | 1 |
| 319 | community-recruited | 5 |
| 320 | des-implanted | 1 |
| 321 | lung-transplanted | 1 |
| 322 | hyperalimented | 1 |
| 323 | 2-footed | 1 |
| 324 | non-adopted | 2 |
| 325 | phase-adjusted | 1 |
| 326 | graft-derived | 1 |
| 327 | saf-preserved | 1 |
| 328 | dtr-preserved | 1 |
| 329 | re-assayed | 1 |
| 330 | non-digitalized | 1 |
| 331 | diet-stabilized | 1 |
| 332 | dddr-randomized | 2 |
| 333 | undialyzed | 2 |
| 334 | 28-wk-old | 3 |
| 335 | 19-wk-old | 1 |
| 336 | 4-10-year-old | 1 |
| 337 | 7-11-year-old | 1 |
| 338 | 7-12-year-old | 1 |
| 339 | 11-33-year-old | 1 |
| 340 | 10-65-year-old | 1 |
| 341 | 45-75-year-old | 1 |
| 342 | 3-7-year-old | 1 |
| 343 | nonthreshold | 3 |
| 344 | two-second | 1 |
| 345 | stable-copd | 1 |
| 346 | non-trd | 1 |
| 347 | deoxyoligonucleotide | 1 |
| 348 | symptoms-free | 1 |
| 349 | end-point-free | 2 |
| 350 | treatmentfree | 1 |
| 351 | known-age | 1 |
| 352 | tourette's/rage | 1 |
| 353 | mmhg.the | 1 |
| 354 | ml/hr.the | 1 |
| 355 | months.the | 5 |
| 356 | authors.the | 1 |
| 357 | days.the | 4 |
| 358 | no-stroke | 1 |
| 359 | photoprovocable | 1 |
| 360 | unascertainable | 1 |
| 361 | undeterminable | 1 |
| 362 | microbiologically-assessable | 1 |
| 363 | evaluatable | 1 |
| 364 | diet-stable | 2 |
| 365 | clinically-stable | 1 |
| 366 | pk-evaluable | 2 |
| 367 | kras-evaluable | 1 |
| 368 | clinically-evaluable | 1 |
| 369 | aruba-eligible | 1 |
| 370 | thrombolytic-eligible | 1 |
| 371 | epoetin-eligible | 1 |
| 372 | induction-eligible | 1 |
| 373 | srs-eligible | 1 |
| 374 | retreatment-eligible | 1 |
| 375 | walpole | 1 |
| 376 | aryloxy-1,3,4-thiadiazole | 1 |
| 377 | non-down-syndrome | 1 |
| 378 | years.eighty-one | 1 |
| 379 | circumferential-type | 1 |
| 380 | resident-care | 2 |
| 381 | emesis-questionnaire | 1 |
| 382 | eradication-failure | 1 |
| 383 | patient-exposure | 3 |
| 384 | antipsychotic-short-exposure | 1 |
| 385 | nonduplicate | 6 |
| 386 | itt/complete | 1 |
| 387 | okt3-rescue | 1 |
| 388 | vedolizumab-naive | 1 |
| 389 | glucocorticoid-naive | 1 |
| 390 | corticosteroid-naive | 2 |
| 391 | dmard-naive | 8 |
| 392 | aspirin-naive | 1 |
| 393 | biopsy-naive | 2 |
| 394 | hundred-five | 3 |
| 395 | pre/hypertensive | 1 |
| 396 | hla-a*0201-negative | 1 |
| 397 | tsab-negative | 1 |
| 398 | carbapenemase-negative | 1 |
| 399 | erg-negative | 1 |
| 400 | pss-negative | 1 |
| 401 | ridt-negative | 2 |
| 402 | community-representative | 1 |
| 403 | hla-a*0201-positive | 4 |
| 404 | hla-a2-positive | 3 |
| 405 | hpev3-positive | 1 |
| 406 | mpo-anca-positive | 1 |
| 407 | pca/ifa-positive | 1 |
| 408 | hypoxia-positive | 3 |
| 409 | ama-m2-negative/ana-positive | 1 |
| 410 | sra-positive | 2 |
| 411 | ab-positive | 6 |
| 412 | tsab-positive | 1 |
| 413 | dth-positive | 1 |
| 414 | htbii-positive | 1 |
| 415 | mayo-negative/ieo-positive | 1 |
| 416 | anti-hmgcr-positive | 2 |
| 417 | mat-positive | 1 |
| 418 | tilt-positive | 1 |
| 419 | alert-positive | 1 |
| 420 | hmpv-positive | 6 |
| 421 | etiology-positive | 1 |
| 422 | consecutive | 10,871 |
| 423 | non-consecutive | 37 |
| 424 | nonconsecutive | 46 |
| 425 | refluxive | 1 |
| 426 | hundred-twelve | 1 |
| 427 | levodopa-naïve | 1 |
| 428 | tne-naïve | 1 |
| 429 | ventilator-naïve | 1 |
| 430 | agonist-naïve | 1 |
| 431 | biopsy-naïve | 1 |
| 432 | mu/min/g | 3 |
| 433 | phase-lag | 1 |
| 434 | xfs/xfg | 1 |
| 435 | non-mbl-producing | 1 |
| 436 | bcg-responding | 1 |
| 437 | early-responding | 1 |
| 438 | norwegian-speaking | 1 |
| 439 | vitrification-warming | 3 |
| 440 | non-adjoining | 1 |
| 441 | infection-bearing | 1 |
| 442 | cocaine-misusing | 1 |
| 443 | agitation-exhibiting | 1 |
| 444 | nonexiting | 2 |
| 445 | nicotinamide-receiving | 1 |
| 446 | lakh | 2 |
| 447 | childish | 4 |
| 448 | rhai | 1 |
| 449 | non-ecfi | 2 |
| 450 | irs-i/ii | 1 |
| 451 | asai-iii | 2 |
| 452 | irs-iii | 2 |
| 453 | nonpmi | 1 |
| 454 | non-aapi | 1 |
| 455 | cross-track | 1 |
| 456 | up-to-2-week | 1 |
| 457 | person-week | 1 |
| 458 | cardiosuigical | 1 |
| 459 | surgical-urological | 1 |
| 460 | clinical/subclinical | 1 |
| 461 | subfasical | 1 |
| 462 | euthyroidal | 1 |
| 463 | db-trial | 2 |
| 464 | controlled-essential | 1 |
| 465 | tetrakaidecahedral | 1 |
| 466 | hexakaidecahedral | 1 |
| 467 | non-periprocedural | 1 |
| 468 | patient-hospital | 2 |
| 469 | c-steel | 1 |
| 470 | years-all | 1 |
| 471 | ml/hr.all | 1 |
| 472 | μg/cvl | 1 |
| 473 | nicdm | 1 |
| 474 | rheem | 1 |
| 475 | non-mpm | 1 |
| 476 | ct-arm | 1 |
| 477 | bioct-arm | 1 |
| 478 | summer-form | 1 |
| 479 | id/autism | 1 |
| 480 | ecuadorean | 2 |
| 481 | mptp-parkinsonian | 1 |
| 482 | adultcretan | 1 |
| 483 | one-hen | 1 |
| 484 | thommen | 1 |
| 485 | consecutively-chosen | 1 |
| 486 | randomly-chosen | 1 |
| 487 | groups.ten | 1 |
| 488 | and-forty-seven | 1 |
| 489 | mg-in | 1 |
| 490 | proteins/protein | 2 |
| 491 | fluastatin | 1 |
| 492 | frequentlyin | 1 |
| 493 | desulfurization-regeneration | 1 |
| 494 | patients-hospitalization | 1 |
| 495 | heat-action | 2 |
| 496 | minimal-congestion | 3 |
| 497 | consecution | 1 |
| 498 | fall-born | 1 |
| 499 | cervico | 1 |
| 500 | years.no | 2 |
| 501 | loup | 1 |
| 502 | heparin-group | 1 |
| 503 | ett-group | 1 |
| 504 | iu-group | 1 |
| 505 | surgery-group | 1 |
| 506 | equi-angular | 1 |
| 507 | non-coplanar | 3 |
| 508 | nullipar | 2 |
| 509 | 18-member | 1 |
| 510 | radioulcer | 1 |
| 511 | movement-disorder | 1 |
| 512 | non-pusher | 1 |
| 513 | high-consumer | 1 |
| 514 | paper-paper | 1 |
| 515 | bladder-catheter | 1 |
| 516 | hernia-repair | 1 |
| 517 | non-fmr | 2 |
| 518 | hundred-thirty-four | 1 |
| 519 | pretur | 2 |
| 520 | non-ids | 2 |
| 521 | haemarthroses | 1 |
| 522 | consecutives | 4 |
| 523 | hiv/adis | 1 |
| 524 | non-psoriasis | 1 |
| 525 | mitral-stenosis | 1 |
| 526 | protozoosis | 1 |
| 527 | prehydronephrosis | 1 |
| 528 | new-to-dialysis | 1 |
| 529 | coating/sampling/analysis | 1 |
| 530 | gastrititis | 1 |
| 531 | arc/ks | 1 |
| 532 | non-lts | 1 |
| 533 | nonedentulous | 2 |
| 534 | racat | 1 |
| 535 | non-iondt | 1 |
| 536 | ty-eight | 1 |
| 537 | glaucomatous/oht | 1 |
| 538 | 'audit | 1 |
| 539 | pupil/adult | 2 |
| 540 | in-compliant | 1 |
| 541 | normal-pregnant | 2 |
| 542 | statin-tolerant | 1 |
| 543 | clofibrate-resistant | 1 |
| 544 | rif-resistant | 1 |
| 545 | relapsed/resistant | 4 |
| 546 | community-resident | 1 |
| 547 | alprazolam-dependent | 1 |
| 548 | hmcs2-deficient | 2 |
| 549 | cd40l-deficient | 3 |
| 550 | acl-insufficient | 1 |
| 551 | 2-row | 2 |
| 552 | either-sex | 1 |
| 553 | split-sex | 1 |
| 554 | hisex | 2 |
| 555 | non-reflux | 1 |
| 556 | pack-a-day | 1 |
| 557 | 250-cgy | 1 |
| 558 | systemically-healthy | 1 |
| 559 | moderate/heavily | 2 |
| 560 | hemo-dynamically | 1 |
| 561 | post-esophagectomy | 1 |
| 562 | pregnany | 1 |
| 563 | fluid-therapy | 1 |
| 564 | geropsychiatry | 1 |
| 565 | limited-activity | 1 |
| 566 | five-forty | 1 |